Cormorant Asset Management’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-2,349,060
| Closed | -$22.6M | – | 67 |
|
|
2023
Q4 | $22.6M | Buy |
2,349,060
+2,295,000
| +4,245% | +$18M | 1.08% | 28 |
|
|
2023
Q3 | $218K | Hold |
54,060
| – | – | 0.01% | 48 |
|
|
2023
Q2 | $384K | Hold |
54,060
| – | – | 0.02% | 62 |
|
|
2023
Q1 | $402K | Hold |
54,060
| – | – | 0.03% | 70 |
|
|
2022
Q4 | $392K | Hold |
54,060
| – | – | 0.03% | 71 |
|
|
2022
Q3 | $524K | Hold |
54,060
| – | – | 0.04% | 70 |
|
|
2022
Q2 | $1.03M | Hold |
54,060
| – | – | 0.08% | 71 |
|
|
2022
Q1 | $2.69M | Hold |
54,060
| – | – | 0.21% | 60 |
|
|
2021
Q4 | $4.08M | Hold |
54,060
| – | – | 0.24% | 58 |
|
|
2021
Q3 | $4.27M | Hold |
54,060
| – | – | 0.17% | 73 |
|
|
2021
Q2 | $7.5M | Sell |
54,060
-3,000
| -5% | -$572K | 0.25% | 69 |
|
|
2021
Q1 | $11.9M | Hold |
57,060
| – | – | 0.27% | 67 |
|
|
2020
Q4 | $9.48M | Hold |
57,060
| – | – | 0.23% | 68 |
|
|
2020
Q3 | $9.69M | Sell |
57,060
-7,466
| -12% | -$1.08M | 0.37% | 59 |
|
|
2020
Q2 | $10.7M | Sell |
64,526
-473
| -0.7% | -$73.8K | 0.41% | 57 |
|
|
2020
Q1 | $7.53M | Hold |
64,999
| – | – | 0.35% | 54 |
|
|
2019
Q4 | $9.61M | Hold |
64,999
| – | – | 0.38% | 52 |
|
|
2019
Q3 | $8.88M | Hold |
64,999
| – | – | 0.54% | 47 |
|
|
2019
Q2 | $8.45M | Sell |
64,999
-2,390
| -4% | -$278K | 0.49% | 52 |
|
|
2019
Q1 | $6.38M | Buy |
+67,389
| New | +$8.86M | 0.43% | 48 |
|
Cormorant Asset Management's HARP Position: Q1 2024 in Review
Cormorant Asset Management sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 2,349,060 shares — an estimated $22.6M sold.
Cormorant Asset Management first reported a position in HARP in Q1 2019 and held it in 20 quarters. The position peaked at $22.6M in Q4 2023. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Cormorant Asset Management reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Cormorant Asset Management sold 2,349,060 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $22.6M.
- Cormorant Asset Management first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 20 quarters.
- Cormorant Asset Management's Harpoon Therapeutics, Inc. Common Stock position peaked at $22.6M in Q4 2023.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Cormorant Asset Management's 13F filing for Q1 2024, filed 15 May 2024.